

Content available at: <https://www.ipinnovative.com/open-access-journals>

IP International Journal of Medical Microbiology and Tropical Diseases

Journal homepage: <https://www.ijmmt.org/>

## Original Research Article

## A new single run polymerase chain reaction assay for cyclosporiasis in immunocompromised patients

Manish Katiyar<sup>1</sup>, Reena Gulati<sup>2</sup>, Sreejith Parameswaran<sup>3</sup>, Abdoul Hamide<sup>4</sup>, Nonika Rajkumari<sup>1</sup>, Rakesh Singh<sup>1,\*</sup><sup>1</sup>Dept. of Microbiology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India<sup>2</sup>Dept. of Paediatrics, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India<sup>3</sup>Dept. of Nephrology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India<sup>4</sup>Dept. of Medicine, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India

## ARTICLE INFO

## Article history:

Received 21-07-2021

Accepted 27-08-2021

Available online 01-09-2021

## Keywords:

Cyclospora cayetanensis

Diarrhea

PCR assay

People living with HIV/AIDS

PLHA

Post-renal transplant

PRT

Modified Ziehl-Neelsen staining

## ABSTRACT

**Background:** *Cyclospora cayetanensis* causes human intestinal cyclosporiasis. It is more common in the immunocompromised patients and mainly seen in people living with HIV/AIDS (PLHA), post-renal transplant (PRT) patients and immunocompromised children (IC). Diagnostic microscopy for the oocysts of the parasite is less sensitive, requiring examination of multiple stool samples. Here we developed a new single run polymerase chain reaction (PCR) assay for the detection of *C. cayetanensis* and it was used to know the hospital based prevalence of cyclosporiasis.

**Materials and Methods:** A cross-sectional study was conducted from June 2016 to October 2020 in a tertiary care teaching hospital. A new single run amplification PCR-based diagnostic assay was developed for *C. cayetanensis*. Stool samples were collected from 121 PLHA, 135 PRT and 79 immunocompromised children (IC) other than PLHA and PRT. All stool samples were examined for the presence of *C. cayetanensis* oocysts as well as tested with new *C. cayetanensis* PCR assay.

**Results:** Modified Ziehl-Neelsen staining of the concentrated stool smear did not reveal oocysts of *Cyclospora* species in any stool specimen. However, new PCR assay detected *C. cayetanensis* in 2 stool specimens – one from a PLHA patient and another from a PRT patient, giving a prevalence of 0.6% (2/335), 0.8% (1/121) in PLHA and 0.7% (1/135) in PRT. It was not detected in IC.

**Conclusion:** Cyclosporiasis is infrequent in southern part of India. The new single run PCR assay developed by us is simple and cost effective molecular assay for the detection of *C. cayetanensis*.

This is an Open Access (OA) journal, and articles are distributed under the terms of the [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License](https://creativecommons.org/licenses/by-nc-sa/4.0/), which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: [reprint@ipinnovative.com](mailto:reprint@ipinnovative.com)

## 1. Introduction

*Cyclospora cayetanensis* (*C. cayetanensis*) is the only pathogenic species of the *Cyclospora* genus responsible for human cyclosporiasis.<sup>1</sup> People living in endemic areas or traveling in endemic countries are more likely to become infected. The intestinal parasite is mainly transmitted by the faecal contamination of food or water. It causes an enteric

disease and presented with acute or chronic diarrhea. Fever, nausea, vomiting, abdominal pain/cramps and weight loss are common manifestations.<sup>2–4</sup> It is an emerging infectious disease with an increasing number of outbreaks reported from developing and developed countries, including the United States of America and Canada.<sup>5</sup> The prevalence of cyclosporiasis was observed from nil to 41.6%.<sup>6</sup> The global prevalence of *C. cayetanensis* in humans is 3.6%.<sup>7</sup> Cyclosporiasis is more common in the immunocompromised patients and mainly seen in people

\* Corresponding author.

E-mail address: [drrakesh1976@yahoo.com](mailto:drrakesh1976@yahoo.com) (R. Singh).

living with HIV/AIDS (PLHA), post-renal transplant (PRT) patients and immunocompromised children (IC). A study from north India observed a prevalence of 2.4% among immunocompromised, immunocompetent and healthy individuals.<sup>8</sup>

Conventional diagnosis of cyclosporiasis is made by microscopic examination of the stool smears.<sup>9</sup> The sensitivity of microscopy depends upon the number of oocysts present in a stool sample. No oocytes may be seen in a stool sample due to intermittent shedding of the oocysts, requiring examination of multiple stool samples to diagnose cyclosporiasis.<sup>9</sup> Commercially available antigen detection tests are expensive, have variable sensitivity and therefore not used in resource-limited countries.<sup>10,11</sup> Molecular diagnosis based on polymerase chain reaction (PCR) has higher sensitivity than microscopy. Analysis of the gene encoding 18S ribosomal ribonucleic acid (rRNA) has shown that this locus of the parasitic deoxyribonucleic acid (DNA) is highly conserved and suitable for molecular detection.<sup>12,13</sup> Diagnostic facilities for this ubiquitous parasite in India is limited to major research facilities. There is a need for a sensitive and reliable diagnostic test. We here report a new single run PCR assay developed by us for the detection of *C. cayetanensis* directly from stool samples and it was used to know the hospital based prevalence of cyclosporiasis.

## 2. Materials and Methods

This cross sectional study was conducted from June 2016 to October 2020 at Department of Microbiology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India. It was approved by the Institute Ethics Committee (Human studies). The PLHA patients were recruited from antiretroviral treatment (ART) clinic, and PRT patients from Department of Nephrology, and immunocompromised children (IC) from Department of Pediatrics. A total of 335 immunocompromised patients were recruited in the study - 121 PLHA group, 135 PRT group, and 79 IC group. Six children on ART were included in the PLHA group, and six PRT children were included in the PRT group. These 12 children were not included in the IC group. The clinico-demographic details of the participants were recorded in a pre-structured proforma. The immunocompromised participants were categorized into two groups, based on the presence or absence of diarrhea.<sup>14</sup> Group 1 includes the patient presented with diarrhea and group 2 includes the patient presented without diarrhea.

### 2.1. Microscopic examination for oocysts of *C. cayetanensis*

Stool samples were concentrated by Sheather's sucrose floatation technique.<sup>15</sup> Modified Ziehl-Neelsen staining of stool smears was performed using 1% concentrated

sulphuric acid and observed microscopically for the presence of oocysts of *C. cayetanensis*.<sup>16</sup>

### 2.2. Molecular assay for cyclosporiasis

A new set primer was designed and PCR assay was standardized for *C. cayetanensis*. All stool samples were tested by PCR.

#### 2.2.1. Designing of Primers

A new set of primer was designed using a sequence common to *C. cayetanensis* (Accession number AF111183.1) and targeting its conserved 18S rRNA gene using NCBI-BLASTn with default settings. Sequences were aligned with CLUSTALW to identify common regions suitable for species-specific primers.<sup>17,18</sup> Primer-3 software (<http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi>) was used and custom-synthesized by Sigma-Aldrich (Merck KGaA, Darmstadt, Germany). The designed Cyclo\_Uni\_F (5'-TTAGCCGGCGATAGATCATT-3') was used as a forward and Cyclo\_Uni\_R (5'-TCAAGAACGACAGTAGGGGG -3') was used as a reverse primer respectively. Primers were examined in silico in SnapGene software (v1.1.3, Chicago, USA) (Figure 1).

#### 2.2.2. DNA extraction from stool samples

DNA was extracted from the stool samples using QIAmp DNA Stool Mini Kit (Qiagen, Hilden, Germany) as per the manufacturer's instructions. The quality and quantity of DNA obtained were evaluated in NanoDrop 2000C (ThermoFisher, Massachusetts, USA). DNA samples were stored at -20 °C until further use.

#### 2.2.3. Quality control for DNA samples

Purified DNA material of *C. cayetanensis* was obtained from the Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India. It was used as a positive control DNA template for standardization and validation of the PCR.

#### 2.2.4. Standardization of PCR

PCR was standardized using new primers, positive control DNA material of *C. cayetanensis* as templates and nuclease-free water as negative controls. Gradient PCR was performed to determine the annealing temperature. PCR reaction was performed with 12.5 µl of commercial 2X Taq DNA polymerase master mix (Ampliqon, Odense, Denmark), 2 µl of DNA template, 0.5 µM each of forward and reverse primers with nuclease-free water to make a final volume of 25 µl on Agilent SureCycler 8800 (Agilent Technologies, California, USA). The cycling conditions of PCR were- initial denaturation at 94 °C for 5 minutes followed by 35 cycles at 94 °C for 45 seconds, 56 °C for 45 seconds, and 72 °C for 45 seconds, followed by a final

extension at 72 °C for 5 minutes. PCR amplicons were visualized in Biorad gel documentation system after 1.2% agarose gel electrophoresis (Figure 1).

#### 2.2.5. Molecular testing of stool samples

All stool samples were tested for cyclosporiasis by PCR. The stool samples which yielded a 713 base pair (bp) product size were considered positive for *C. cayetanensis*. If 713 bp of band was not seen then the sample was considered negative for *C. cayetanensis*.

#### 2.3. Statistical analysis

Continuous variables were expressed as mean  $\pm$  SD. Categorical variables were expressed as frequency/percentage and compared using chi-square and fisher's exact test. A P value of less than 0.05 was considered statistically significant.

### 3. Results

A total of 335 immunocompromised participants were recruited during the study period. It was divided into three groups - 121 PLHA group, 135 PRT group, and 79 IC group. Two hundred and ten (62.7%) were males, and 125 (37.3%) were females. Males were predominant in PLHA (60.3%) and PRT (74.8%) group, while females were predominant in IC (54.4%) group. Most patients of PLHA and PRT groups were in age from 19 to 45 years. One hundred and forty-nine (44.5%) participants were living in rural area - 45 (37.2%) in PLHA, 58 (43%) in PRT and 46 (58.2%) in IC. Two-third participants were using municipal water - 98 (81%) in PLHA, 77 (57%) in PRT and 73 (92.4%) in IC. Majority used municipal water. A little more than half participants had pets in their houses 72 (59.5%) in PLHA, 72 (53.3%) in PRT and 51 (64.6%) in IC. Patients presented with diarrhea were 186 (55.5%) – 76 (62.8%) in PLHA, 44 (32.6%) in PRT and 66 (83.5%) in IC. Only thirteen children presented without diarrhea in the IC group; therefore the IC group is not analyzed further based on diarrhea. The clinico-demographic details of the PLHA and PRT group are depicted in Tables 1 and 2, respectively. Only few participants in all the three groups presented with other clinical signs and symptoms along with diarrhea like nausea/vomiting, abdominal pain, weight loss or malnutrition. Abdominal pain was the most common symptom observed with diarrhea - 9 (7.4%) in PLHA, 8 (5.9%) in PRT and 4 (5.1%) in IC.

Microscopic observation of stool samples from all 335 participants did not reveal any oocysts of *C. cayetanensis*. The PCR test developed by us (Figure 1), on the other hand, revealed two positive results, one in PLHA group and another in PRT group. None of the stool samples from children were positive. The overall prevalence of *C. cayetanensis* was 0.6% (2/335), 0.8% (1/121) in PLHA

and 0.7% (1/135) in PRT. The PLHA patient was 46 years old male who presented with diarrhea, abdominal pain, nausea/vomiting and weakness and PRT positive patient was 43 year old, male with no signs and symptoms. Both positive patients were living in urban area, used municipality water and had pets in their houses.

### 4. Discussion

The coccidian parasite - *C. cayetanensis* causes cyclosporiasis in human, which is linked to large food and water-borne outbreaks throughout the world. Availability of food items imported from different parts of the world has led to globalization of the disease.<sup>1</sup> Cyclosporiasis is a very widespread disease even in developed countries like United States and Canada. In 2017, a total of 1,065 cases were recorded in 40 states of the United States.<sup>19</sup> The prevalence of cyclosporiasis in India is extremely variable and ranging from 0.7% to 22.2%.<sup>3,5</sup> It is not reported much from the southern part of India.

Most of the studies used only microscopy for diagnosis. Very few studies used PCR techniques for the detection of *C. cayetanensis*. We developed a robust and precise single run PCR assay for the detection of *C. cayetanensis*. It was developed using a new set of primers targeting the conserved region of the 18S rRNA gene, though there are limited genomic data available for *C. cayetanensis* making it difficult to develop specific primers.

We collected stool samples from 335 various immunocompromised patients – 121 PLHA, 135 PRT and 79 IC patients. The microscopy did not detect any positive case of cyclosporiasis, the PCR assay detected 2 positive cases, one was PLHA symptomatic patient and another was PRT asymptomatic patients. Here we observed that molecular assays are more sensitive than conventional microscopic methods. None of the IC were positive for cyclosporiasis by either method. It indicates that the overall prevalence of cyclosporiasis is low in southern part of India and observed as 0.6% (2/335), 0.8% (1/121) in PLHA and 0.7% (1/135) in PRT.


A study carried out by Gupta et al. detected *Cyclospora* spp. in one of 250 stool samples from 113 adult PLHA positive patients by microscopy and who was symptomatic.<sup>20</sup> The positive PLHA case in the study was also symptomatic. A few studies have reported prevalence of cyclosporiasis in PRT patients. We detected a single case of cyclosporiasis and a prevalence of 0.7% in the PRT group. The positive PRT patient in this study was asymptomatic and potential to become symptomatic later if left undiagnosed, while timely detection and treatment could prevent later disease and complication. A study conducted in Turkey reported a 10% prevalence of *Cyclospora* spp. in PRT patients.<sup>21</sup> While a similar study from Iran did not detect cyclosporiasis in any of their PRT patients.<sup>22</sup> Yadav et al. from New Delhi, India reported

**Table 1:** Clinico-demographic details of PLHA patients. Group 1: Patients presented with diarrhea; Group 2: Patients presented without diarrhea

Variables	Total (n=121)	Group 1 (n=76; 62.8%)	Group 2 (n=45; 37.2%)	P value
<b>Age</b>				
≤18	6 (5.0%)	6 (7.9%)	0	0.073
19-45	72 (59.5%)	46 (60.5%)	26 (57.8%)	
46-60	40 (33.1%)	21 (27.6%)	19 (42.2%)	
>60	3 (2.5%)	3 (4.0%)	0	
<b>Gender</b>				
Male	73 (60.3%)	47 (61.8%)	26 (57.8%)	0.659
Female	48 (39.7%)	29 (38.2%)	19 (42.2%)	
<b>Fever</b>	3 (2.5%)	3 (4.0%)	0	
<b>Nausea/Vomiting</b>	4 (3.3%)	4 (5.3%)	0	
<b>Abdominal pain</b>	9 (7.4%)	9 (11.8%)	0	
<b>Weight loss</b>	4 (3.3%)	4 (5.3%)	0	
<b>Weakness</b>	7 (95.8%)	7 (9.2%)	0	
<b>Malnutrition</b>	3 (2.5%)	3 (4.0%)	0	
<b>Residence</b>				
Rural	45 (37.2%)	30 (39.5%)	15 (33.3%)	0.499
Urban	76 (62.8%)	46 (60.5%)	30 (66.7%)	
<b>Water source</b>				
Municipality water	98 (81.0%)	63 (82.9%)	35 (77.8%)	0.488
Filtered water	23 (19.0%)	13 (17.1%)	10 (22.2%)	
<b>Pet animal in house</b>				
Pet animal	72 (59.5%)	45 (59.2%)	27 (60.0%)	0.932
No pet animal	49 (40.5%)	31 (40.8%)	18 (40.0%)	

**Table 2:** Clinico-demographic details of post-renal transplant patients. Group 1: Patients presented with diarrhea; Group 2: Patients presented without diarrhea

Variables	Total n=135	Group 1 (n=44; 32.6%)	Group 2 (n=91; 67.4%)	P value
<b>Age</b>				
≤ 18	6 (4.4%)	1 (2.3%)	5 (5.5%)	0.703
19-45	112 (83.0%)	6 (81.8%)	76 (83.5%)	
46-60	17 (12.6%)	7 (15.9%)	10 (11.0%)	
<b>Gender</b>				
Male	101 (74.8%)	29 (65.9%)	72 (79.1%)	0.097
Female	34 (25.2%)	15 (34.1%)	19 (20.9%)	
<b>Fever</b>	4 (3.0%)	4 (9.1%)	0	
<b>Nausea/Vomiting</b>	4 (3.0%)	4 (9.1%)	0	
<b>Abdominal pain</b>	8 (5.9%)	7 (15.9%)	0	
<b>Weight loss</b>	4 (3.0%)	3 (6.8%)	0	
<b>Weakness</b>	6 (4.4%)	6 (13.6%)	0	
<b>Malnutrition</b>	2 (1.5%)	2 (4.6%)	0	
<b>Residence</b>				
Rural	58 (43.0%)	25 (56.8%)	33 (36.3%)	0.024
Urban	77 (57.0%)	19 (43.2%)	58 (63.7%)	
<b>Water source</b>				
Municipality water	77 (57.0%)	25 (56.8%)	52 (57.1%)	0.972
Filtered water	58 (42.0%)	19 (43.2%)	39 (42.9%)	
<b>Pet animal in house</b>				
Pet animal	72 (53.3%)	23 (52.3%)	49 (53.9%)	0.864
No pet animal	63 (46.7%)	21 (47.7%)	42 (46.2%)	



**Fig. 1:** A. Gel electrophoresis of PCR assay for *C. cayetanensis*; Lane 1 100 bp DNA ladder, Lane 2 positive control (713 bp); Lane 3 & 6 positive samples; Lane 4 & 5 negative samples; Lane 7 negative control. B. Primer-binding sites primer for *C. cayetanensis* by SnapGene software (v1.1.3)

2.4% prevalence of cyclosporiasis in PRT patients and is higher than the current study. They detected it by nested PCR-Restriction Fragment Length Polymorphism (RFLP) which is a two run PCR amplification assay and followed by RFLP.<sup>8</sup> Our PCR is a single run amplification assay and without the need for RFLP. Hence it is a simple, rapid and cost effective molecular assay.

We did not detect a single case of cyclosporiasis in 79 IC patients. It indicates that the low prevalence of cyclosporiasis in southern region of India. A hospital based study from Mexico reported a prevalence of 0.67% among children with diarrhea over a 9-year period, majority diagnosed during the rainy season.<sup>23</sup> Massoud et al. from Egypt reported 17% prevalence in symptomatic and 6% in asymptomatic immune-competent children less than five years old.<sup>24</sup> Hence prevalence of cyclosporiasis is highly variable with geographical area and climate and therefore there is a need for continuous study to monitor

its prevalence.

Though less common than other intestinal coccidian parasites, cyclosporiasis is an emerging disease with increasing number of outbreaks reported from different parts of the world.<sup>18,25</sup> Non-availability of simple molecular assay hampers the diagnosis. The development of a reliable, simple and cost effective test can help in making the test available in resource limited countries for its diagnosis.

This is the first study in India where indigenous primers were designed and studied for the detection of cyclosporiasis to the best of our knowledge. Furthermore, this new PCR assay can be used to study genetic diversity or phylogenetic analysis as the product size of the PCR is 713 bp size. The PCR assay has been validated using positive control, in-silico examination, expected product size in gel electrophoresis. Although the prevalence of cyclosporiasis is low in our region but this assay has the potential to diagnosis cases of cyclosporiasis.

## 5. Conclusion

Cyclosporiasis is infrequent in our region. A new single step PCR assay was developed which is simple, rapid, cost effective and has a potential to study genetic diversities of *C. cayetanensis*.

## 6. Acknowledgements

The authors thank Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS) Lucknow, India for providing DNA material of *C. cayetanensis* for the study.

## 7. Source of Funding

The study was supported by Intramural Research Grant from Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India.

## 8. Conflict of interest

All contributing authors declare no conflicts of interest

## References

- Giangaspero A, Gasser RB. Human cyclosporiasis. *Lancet Infect Dis*. 2019;19(7):226–36.
- Ortega YR, Roxas CR, Gilman RH, Miller NJ, Cabrera L, Taquiri C, et al. Isolation of *Cryptosporidium parvum* and *Cyclospora cayetanensis* from vegetables collected in markets of an endemic region in Peru. *Am J Trop Med Hyg*. 1997;57(6):683–6.
- Connor BA, Reidy J, Soave R. Cyclosporiasis: clinical and histopathologic correlates. *Clin Infect Dis*. 1999;28(6):1216–22.
- Checkley W, White AC, Jaganath D, Arrowood MJ, Chalmers RM, Chen XM, et al. A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for *Cryptosporidium*. *Lancet Infect Dis*. 2015;15(1):85–94.
- Dixon BR. Parasitic illnesses associated with the consumption of fresh produce—an emerging issue in developed countries. *Curr Opin Food Sci*. 2016;8(4):104–9.
- Almeria S, Cinar HN, Dubey JP. *Cyclospora cayetanensis* and cyclosporiasis: an update. *Microorganisms*. 2019;7(9):317.
- Li J, Wang R, Chen Y, Xiao L, Zhang L. *Cyclospora cayetanensis* infection in humans: Biological characteristics, clinical features, epidemiology, detection method and treatment. *Parasitology*. 2020;147(2):160–70.
- Yadav P, Khalil S, Mirdha BR, Makharia GK, Bhatnagar S. Molecular characterization of clinical isolates of *Cyclospora cayetanensis* from patients with diarrhea in India. *Indian J Med Microbiol*. 2015;33(3):351–6.
- Fletcher SM, Stark D, Harkness J, Ellis J. Enteric protozoa in the developed world: a public health perspective. *Clin Microbiol Rev*. 2012;25(3):420–49.
- Hussein EM, El-Moamly AA, Dawoud HA, Fahmy H, El-Shal HE, Sabek NA, et al. Real-time PCR and flow cytometry in detection of *Cyclospora* oocysts in fecal samples of symptomatic and asymptomatic pediatrics patients. *J Egypt Soc Parasitol*. 2007;37(1):151–70.
- Plutzer J, Karanis P. Neglected waterborne parasitic protozoa and their detection in water. *Water Res*. 2016;101:318–32. doi:10.1016/j.watres.2016.05.085.
- Jinneman KC, Wetherington JH, Hill WE, Adams AM, Johnson JM, Tenge BJ, et al. Template preparation for PCR and RFLP of amplification products for the detection and identification of *Cyclospora* spp. and *Eimeria* spp. oocysts directly from raspberries. *J Food Prot*. 1998;61(11):1497–503.
- Shields JM, Olson BH. PCR-restriction fragment length polymorphism method for detection of *Cyclospora cayetanensis* in environmental waters without microscopic confirmation. *Appl Environ Microbiol*. 2003;69(8):4662–9.
- World Health Organization. (1993). The Management and prevention of diarrhoea : practical guidelines, 3rd ed. World Health Organization. Available from: <https://apps.who.int/iris/handle/10665/37036>.
- Iyer RN, Rao JR, Venkatalakshmi A, Nahdi FB. Clinical and microbiology profile and outcome of diarrhea by coccidian parasites in immunocompetent children. *Pediatr Infect Dis J*. 2015;34(9):937–9.
- Dryden MW, Payne PA, Ridley R, Smith V. Comparison of common fecal flotation techniques for the recovery of parasite eggs and oocysts. *Vet Ther*. 2005;6(1):15–28.
- Kumar S, Stecher G, Tamura K. MEGA7: molecular evolutionary genetics analysis version 7.0 for bigger datasets. *Mol Biol Evol*. 2016;33(7):1870–4.
- Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. *Nucleic Acids Res*. 1994;22(22):4673–80.
- Ozpinar N, Karaman U. The prevalence of *Cyclospora cayetanensis* in patients with gastrointestinal system complaints. *Cumhuriyet Derg*. 2018;40(4):408–12.
- Gupta S, Narang S, Nunavath V, Singh S. Chronic diarrhoea in HIV patients: prevalence of coccidian parasites. *Indian J Med Microbiol*. 2008;26(2):172–5.
- Kilbaş ZG, Yenicesu M, Araz E, Tanyüksel M. *Cyclospora cayetanensis* infection in a patient with renal transplant. *Türk Hij ve Deneysel Biyol Derg*. 2009;66(1):25–7.
- Azami M, Sharifi M, Hejazi SH, Tazhibi M. Intestinal parasitic infections in renal transplant recipients. *Brazilian J Infect Dis*. 2010;14(1):15–8.
- Orozco-Mosqueda GE, Martínez-Loya OA, Ortega YR. *Cyclospora cayetanensis* in a pediatric hospital in Morelia, México. *Am J Trop Med Hyg*. 2014;91(3):537–40.
- Massoud NM, Said DE, El-Salamouny AR. Prevalence of *Cyclospora cayetanensis* among symptomatic and asymptomatic immune-competent children less than five years of age in Alexandria, Egypt. *Alexandria J Med*. 2012;48(3):251–9.
- Chacín-Bonilla L, Barrios F. *Cyclospora cayetanensis*: biology, environmental distribution and transfer. *Biomédica*. 2011;31(1):132–44.

## Author biography

**Manish Katiyar**, PhD Student

**Reena Gulati**, Additional Professor

**Sreejith Parameswaran**, Professor

**Abdoul Hamide**, Senior Professor

**Nonika Rajkumari**, Associate Professor

**Rakesh Singh**, Professor  <https://orcid.org/0000-0002-2213-3993>

**Cite this article:** Katiyar M, Gulati R, Parameswaran S, Hamide A, Rajkumari N, Singh R. A new single run polymerase chain reaction assay for cyclosporiasis in immunocompromised patients. *IP Int J Med Microbiol Trop Dis* 2021;7(3):207–212.